Copyright
©The Author(s) 2022.
World J Gastroenterol. Aug 14, 2022; 28(30): 4120-4132
Published online Aug 14, 2022. doi: 10.3748/wjg.v28.i30.4120
Published online Aug 14, 2022. doi: 10.3748/wjg.v28.i30.4120
Figure 1 Fusobacterium nucleatum levels in different groups.
A: Fusobacterium nucleatum (Fn) levels in normal control, atrophic gastritis (AG), non-AG, gastric polyps, and gastric cancer (GC) groups; B: Fn levels in different TNM stages of GC patients. Red lines represent the median. aP < 0.001, bP < 0.05 (Mann-Whitney U test). NC: Normal controls; NAG: Non-atrophic gastritis; GP: Gastric polyps; AG: Atrophic gastritis; GC: Gastric cancer; Fn: Fusobacterium nucleatum.
- Citation: Chen WD, Zhang X, Zhang MJ, Zhang YP, Shang ZQ, Xin YW, Zhang Y. Salivary Fusobacterium nucleatum serves as a potential diagnostic biomarker for gastric cancer. World J Gastroenterol 2022; 28(30): 4120-4132
- URL: https://www.wjgnet.com/1007-9327/full/v28/i30/4120.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i30.4120